Arcadia Biosciences $4M Private Placement

Arcadia Biosciences, a producer of wellness products, announced a private placement of 3,883,496 shares of its common stock and associated preferred investment options at a purchase price of $1.03 per share. The offering, priced at-the-market under Nasdaq-100 rules, is expected to generate approximately $4 million in gross proceeds. H.C. Wainwright & Co. is serving as the exclusive placement agent. The net proceeds will be utilized for working capital and general corporate purposes. The Series A-1 preferred investment options will be exercisable upon stockholder approval, while Series A-2 preferred investment options are immediately exercisable. The offering is anticipated to close around June 12, 2026, subject to customary closing conditions. The securities were offered under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, and Arcadia Biosciences has committed to filing registration statements with the SEC for the resale of these unregistered securities.